PDF herunterladen
Horm Metab Res 2017; 49(08): 595-603
DOI: 10.1055/s-0043-113635
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy

Marina Willibald
1   University of Düsseldorf, Department of Obstetrics and Gynecology, Düsseldorf, Germany
,
Isabel Wurster
2   Center of Neurology Department of Neurodegenerative Diseases Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
,
Christoph Meisner
3   Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany
,
Ulrich Vogel
4   Institute of Pathology, University of Tübingen, Tübingen, Germany
,
Harald Seeger
5   Department of Women’s Health, University Hospital and Faculty of Medicine, University of Tübingen, Tübingen, Germany
,
Alfred O. Mueck
5   Department of Women’s Health, University Hospital and Faculty of Medicine, University of Tübingen, Tübingen, Germany
,
Tanja Fehm
1   University of Düsseldorf, Department of Obstetrics and Gynecology, Düsseldorf, Germany
,
Hans Neubauer
1   University of Düsseldorf, Department of Obstetrics and Gynecology, Düsseldorf, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 14. Dezember 2016

accepted 12. Juni 2017

Publikationsdatum:
12. Juli 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

PGRMC1 is known to be highly expressed in breast cancer tissue and is associated with chemoresistance in breast cancer cells. However, its role in breast cancer signaling is not fully understood yet. In the present study, the expression status of PGRMC1 and its phosphorylated version (pPGRMC1) in breast cancer tissue and surrounding stroma before and after neoadjuvant therapy was examined to find a possible association to therapy response. Tissue biopsies of 69 breast cancer patients were analyzed by immunohistochemistry for expression levels of PGRMC1 and pPGRMC1. Expression status of PGRMC1 and pPGRMC1 in tumor tissue was compared with expression status of progesterone receptor (PR), estrogen receptor α (ERα), total estrogen receptor β (ERβ), ERβ1, ERβ2, the proliferation marker Ki-67, and human epidermal growth factor receptor 2 (HER2/neu). Correlations were calculated for expression of PGRMC1 and pPGRMC1 before and after neoadjuvant-therapy. PGRMC1 and pPGRMC1 were highly abundant in every breast cancer tissue sample. Considerably lower signals were detected in surrounding tissue. Further, PGRMC1 and pPGRMC1 abundance was found to correlate with ERβ expression. A lower level of pPGRMC1 could be found in post-therapy surgical specimens compared to specimens before treatment. Interestingly, patients with high PGRMC1 tumor levels showed worse response to anthracycline-based therapy as patients with lower PGRMC1 levels. These new findings demonstrate that PGRMC1 might play an important role in progression and therapy resistance of human breast tumors and could offer an interesting target for anticancer therapy.

Key words

PGRMC1 - hormone receptors - estrogen receptors - breast cancer therapy - chemoresistance

Supporting Information

    Supporting Information for this article is available online at http://www.thieme-connect.de/products
  • Supporting Information
 

  • References

  • 1 Frank GA, Danilova NV, Andreeva II, Nefedova NA. WHO classification of tumors of the breast, 2012. Arkh Patol 2013; 75: 53-63
    PubMedGoogle Scholar
  • 2 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
    CrossrefPubMedGoogle Scholar
  • 3 Diessner J, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wöckel A, Bartmann C. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer 2016; 16: 307
    CrossrefPubMedGoogle Scholar
  • 4 Santa-Maria CA, Camp M, Cimino-Mathews A, Harvey S, Wright J, Stearns V. Neoadjuvant therapy for early-stage breast cancer: Current practice, controversies, and future directions. Oncol Williston Park N 2015; 29: 828-838
    PubMedGoogle Scholar
  • 5 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol Poznan Pol 2016; 20: 93-101
    PubMedGoogle Scholar
  • 6 Loibl S, Denkert C, von Minckwitz G. Neoadjuvant treatment of breast cancer--Clinical and research perspective. Breast Edinb Scotl 2015; 24 (Suppl. 02) S73-S77
    PubMedGoogle Scholar
  • 7 Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752
    CrossrefPubMedGoogle Scholar
  • 8 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
    CrossrefPubMedGoogle Scholar
  • 9 Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, Fehm T, Cahill MA. Breast cancer proteomics reveals correlation between Estrogen Receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10: R85
    CrossrefPubMedGoogle Scholar
  • 10 Zhang Y, Ruan X, Willibald M, Seeger H, Fehm T, Neubauer H, Mueck AO. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2016; 32: 58-60
    PubMedGoogle Scholar
  • 11 Ahmed IS, Rohe HJ, Twist KE, Craven RJ. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010; 285: 24775-24782
    CrossrefPubMedGoogle Scholar
  • 12 Hampton KK, Stewart R, Napier D, Claudio PP, Craven RJ. PGRMC1 elevation in multiple cancers and essential role in stem cell survival. Adv Lung Cancer Irvine 2015; 4: 37-51
    PubMedGoogle Scholar
  • 13 Mir SUR, Ahmed ISA, Arnold S, Craven RJ. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 2012; 131: E1-E9
    CrossrefPubMedGoogle Scholar
  • 14 Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, Brucker S, Neubauer H. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause (New York, N.Y.) 2017; 24: 203-209
    CrossrefPubMedGoogle Scholar
  • 15 Ji S, Wu A, Yang H. Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 635-638
    PubMedGoogle Scholar
  • 16 Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, Sugase K, Shimamura T, Ohmura M, Muraoka K, Yamamoto A, Uchida T, Iwata S, Yamaguchi Y, Krayukhina E, Noda M, Handa H, Ishimori K, Uchiyama S, Kobayashi T, Suematsu M. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun 2016; 7: 11030
    CrossrefPubMedGoogle Scholar
  • 17 Lin S-T, May EWS, Chang J-F, Hu R-Y, Wang LH-C, Chan H-L. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. Cell Mol Life Sci 2015; 72: 2395-2409
    CrossrefPubMedGoogle Scholar
  • 18 Friel AM, Zhang L, Pru CA, Clark NC, McCallum ML, Blok LJ, Shioda T, Peluso JJ, Rueda BR, Pru JK. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Lett 2015; 356: 434-442
    CrossrefPubMedGoogle Scholar
  • 19 Zhu X, Han Y, Fang Z, Wu W, Ji M, Teng F, Zhu W, Yang X, Jia X, Zhang C. Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling. Oncol Rep 2013; 30: 2488-2494
    CrossrefPubMedGoogle Scholar
  • 20 Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK. Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 2009; 150: 4846-4854
    CrossrefPubMedGoogle Scholar
  • 21 Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, Fehm T, Mueck AO. Possible role of PGRMC1 in breast cancer development. Climacteric J Int Menopause Soc 2013; 16: 509-513
    PubMedGoogle Scholar
  • 22 Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig 2011; 6: 185-192
    PubMedGoogle Scholar
  • 23 Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, Mafuvadze B, Hyder SM, Fehm T, Mueck AO. Overexpression of progesterone receptor membrane component 1: Possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause (New York, N. Y.) 2013; 20: 504-510
    PubMedGoogle Scholar
  • 24 Mueck AO, Ruan X, Seeger H, Fehm T, Neubauer H. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol 2014; 142: 62-67
    CrossrefPubMedGoogle Scholar
  • 25 Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, Cahill MA, Seeger H, Mueck AO. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric J Int Menopause Soc 2012; 15: 467-472
    PubMedGoogle Scholar
  • 26 Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005; 96: 95-108
    CrossrefPubMedGoogle Scholar
  • 27 Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. WHI Investigators . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253
    CrossrefPubMedGoogle Scholar
  • 28 Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT. WHI Investigators . Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647-1657
    CrossrefPubMedGoogle Scholar
  • 29 Beral V, Reeves G, Bull D, Green J. Million Women Study Collaborators . Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103: 296-305
    CrossrefPubMedGoogle Scholar
  • 30 Cahill MA, Jazayeri JA, Kovacevic Z, Richardson DR. PGRMC1 regulation by phosphorylation: Potential new insights in controlling biological activity!. Oncotarget 2016; 7: 50822-50827
    CrossrefPubMedGoogle Scholar
  • 31 Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR. The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochim Biophys Acta 2016; 1866: 339-349
    PubMedGoogle Scholar
  • 32 Wurster M, Ruoff A, Meisner C, Seeger H, Vogel U, Juhasz-Böss I, Solomayer E, Wallwiener D, Fehm T, Neubauer H. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer. Oncol Rep 2010; 24: 653-659
    PubMedGoogle Scholar
  • 33 Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994; 54: 552-558
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 34 Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-140
    PubMedGoogle Scholar
  • 35 Clark NC, Friel AM, Pru CA, Zhang L, Shioda T, Rueda BR, Peluso JJ, Pru JK. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biol Ther 2016; 17: 262-271
    CrossrefPubMedGoogle Scholar
  • 36 Difilippantonio S, Chen Y, Pietas A, Schlüns K, Pacyna-Gengelbach M, Deutschmann N, Padilla-Nash HM, Ried T, Petersen I. Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer Oxf Engl 1990; 2003 39: 1936-1947
    PubMedGoogle Scholar
  • 37 Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol J Int Soc Oncodevelopmental Biol Med 2005; 26: 142-146
    PubMedGoogle Scholar
  • 38 Hand RA, Craven RJ. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem 2003; 90: 534-547
    CrossrefPubMedGoogle Scholar
  • 39 Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, Cohn MA, Cantley LC, Gygi SP. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 2004; 101: 12130-12135
    CrossrefPubMedGoogle Scholar
  • 40 Min L, Strushkevich NV, Harnastai IN, Iwamoto H, Gilep AA, Takemori H, Usanov SA, Nonaka Y, Hori H, Vinson GP, Okamoto M. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J 2005; 272: 5832-5843
    CrossrefPubMedGoogle Scholar
  • 41 Peluso JJ, Lodde V, Liu X. Progesterone regulation of progesterone receptor membrane component 1 (PGRMC1) sumoylation and transcriptional activity in spontaneously immortalized granulosa cells. Endocrinology 2012; 153: 3929-3939
    CrossrefPubMedGoogle Scholar
  • 42 Peluso JJ, DeCerbo J, Lodde V. Evidence for a genomic mechanism of action for progesterone receptor membrane component-1. Steroids 2012; 77: 1007-1012
    CrossrefPubMedGoogle Scholar
  • 43 Löfgren L, Sahlin L, Von Schoultz B, Fernstad R, Skoog L, Von Schoultz E. Expression of sex steroid receptor subtypes in normal and malignant breast tissue – a pilot study in postmenopausal women. Acta Oncol Stockh Swed 2006; 45: 54-60
    PubMedGoogle Scholar
  • 44 Gohno T, Seino Y, Hanamura T, Niwa T, Matsumoto M, Yaegashi N, Oba H, Kurosumi M, Takei H, Yamaguchi Y, Hayashi S-I. Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance. Cancer Med 2012; 1: 328-337
    CrossrefPubMedGoogle Scholar
  • 45 Lyng MB, Lænkholm A-V, Tan Q, Vach W, Gravgaard KH, Knoop A, Ditzel HJ. Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: A DBCG study. PloS One 2013; 8: e54078
    CrossrefPubMedGoogle Scholar